CD44 and endometrial carcinoma: Furthermore, CD133 together with other markers (e.g., CD44), were used to isolate and enrich carcinoma-initiating cells (CICs) from endometrial carcinoma cell lines, and those cells were also more resistant to the inhibition of growth when treated with cisplatin and paclitaxel, and formed tumors more easily in vivo [25].